Browse News
Filter News
Found 644,611 articles
-
The drug, a combination of cabotegravir and rilpivirine, is a complete therapy for HIV-1 infection in adults who are virologically suppressed.
-
A Look at This Week’s Biotech IPOs
1/22/2021
The 2021 trend of biotech initial public offerings (IPOs) continued this week. Here’s a look. -
One year and more than 410,000 deaths later, the United States is still firmly in the grips of the COVID-19 pandemic.
-
With the Pfizer-BioNTech and Moderna COVID-19 vaccines currently authorized in the U.S. and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for its one-shot vaccine.
-
GSK has discontinued a Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody aimed at treating ulcerative colitis licensed from Immutep Limited following an interim assessment of an Independent Data Monitoring Committee.
-
BioSpace Movers & Shakers, Jan. 22
1/22/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Ten pharmaceutical companies have joined forces again to launch Accumulus Synergy Inc., a non-profit effort to pool data in the cloud and interact with regulators, in the hopes of speeding the drug approval process.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Americans are still hesitant to be vaccinated against COVID-19, according to just-released research from Invisibly.
-
Despite the rising number of COVID-19 cases reported across the globe, rates of influenza have virtually flatlined across the Northern Hemisphere, leading many doctors and researchers to wonder how this could be replicated in non-pandemic times.
-
Amyris Acquiring Terasana Brand To Offer Clean Cannabinoid Consumer Products
1/22/2021
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced that it will expand its portfolio of consumer brands by launching a new range of Terasana
-
/R E P E A T -- Notice to the media - COVID-19 Update (January 22, 2021) - Ministers and Government of Canada officials to hold a news conference on coronavirus disease/
1/22/2021
Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19). Date January 22, 2021 Time 12:30 PM (EST) Location The news conference will be held virtually. Journalists who wish to ask questions can do so by teleconference. Toll-free ( Canada /US) di
-
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
1/22/2021
Exelixis Announces U.S. FDA Approval of CABOMETYX ® (cabozantinib) in Combination with OPDIVO ® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
-
Happiness Biotech Announces Financial Results for the Six Months Ended September 30, 2020 and Provides Guidance For the Whole Fiscal Year Ending March 31, 2021
1/22/2021
Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovative China-based nutraceutical and dietary supplements producer, today announced its unaudited financial results for the six months ended September 30, 2020 and provided the guidance for the whole fiscal year ending March 31, 2021.
-
Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement
1/22/2021
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on January 21, 2021 the Company received formal notice that Jaguar has regained compliance with the bid price requirement, as required by the decision of the Nasdaq Hearings Panel (the "Panel") dated October 28, 2020 (the "Decision").
-
U.S. Food and Drug Administration Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
1/22/2021
U.S. Food and Drug Administration Approves OPDIVO ® (nivolumab) in Combination with CABOMETYX ® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
-
Asia Green Biotechnology Corp. Announces Appointment of Alisdair Leeson To Board of Directors
1/22/2021
Asia Green Biotechnology Corp. ("AGB" or the "Company") (CSE:ASIA), announced today that, subject to regulatory approval, Mr. Alisdair Leeson, CA, has been appointed as a member of the Board of Directors.
-
BirchBioMed Inc. Announces Positive Topline Data from Phase 2 Study of FS2 for Treatment of Keloid Scars
1/22/2021
BirchBioMed Inc., a clinical-stage immunology company focused on the prevention and reduction of immunological fibrotic conditions and defects in the immune system, has announced statistically significant, positive results of a double-blind study
-
Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule
1/22/2021
Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, previously received notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company not having timely filed its Quarterly Report on Form 10-Q for the three months ended September 30, 2020 (the “Form 10-Q”) with the Securities and Exchange Commission.
-
COVID-19 Research Published in The Lancet Rheumatology Finds Rheumatic Disease Patients are at a Reduced Likelihood of Severe Outcomes Now vs. Early Days of Pandemic
1/22/2021
TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), announced the publication of a COVID-19 study using real-world data (RWD) from the company's network.